These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 38056314)

  • 1. Effectiveness and tolerability of antifibrotics in rheumatoid arthritis-associated interstitial lung disease.
    Juge PA; Hayashi K; McDermott GC; Vanni KMM; Kowalski E; Qian G; Bade K; Saavedra A; Dieudé P; Dellaripa PF; Doyle TJ; Sparks JA
    Semin Arthritis Rheum; 2024 Feb; 64():152312. PubMed ID: 38056314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antifibrotics in rheumatoid arthritis-associated interstitial lung disease - real-world data from a nationwide cohort.
    Duarte AC; Marques Gomes C; Correia M; Mendes B; Mazeda C; Guimarães F; Abelha-Aleixo J; Guerra M; Pereira da Costa R; Meirinhos T; Santos MJ
    ARP Rheumatol; 2024; 3(3):182-188. PubMed ID: 39368099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Forced vital capacity trajectories and risk of lung transplant and ILD-related mortality among patients with rheumatoid arthritis-associated interstitial lung disease.
    Venkat RK; Hayashi K; Juge PA; McDermott G; Paudel M; Wang X; Vanni KMM; Kowalski EN; Qian G; Bade KJ; Saavedra AA; Mueller KT; Chang SH; Dellaripa PF; Weinblatt ME; Shadick NA; Doyle TJ; Dieude P; Sparks JA
    Clin Rheumatol; 2024 Aug; 43(8):2453-2466. PubMed ID: 38898318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of antifibrotic agents in the treatment of CTD-ILD and RA-ILD: A systematic review and meta-analysis.
    Yang M; Wu Y; Liu X; Zhao C; Li T; Li T; Zhang X; Jiang H; Mao B; Liu W
    Respir Med; 2023 Sep; 216():107329. PubMed ID: 37315742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antifibrotics in the Management of Rheumatoid Arthritis-Associated Interstitial Lung Disease: Prospective Real-World Experience From an Interstitial Lung Disease Clinic in India.
    Behera AK; Kumar V; Sharma P; Ganga R; Meher J; Pati S; Sinha K
    Cureus; 2024 Jun; 16(6):e63518. PubMed ID: 39081417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study.
    Solomon JJ; Danoff SK; Woodhead FA; Hurwitz S; Maurer R; Glaspole I; Dellaripa PF; Gooptu B; Vassallo R; Cox PG; Flaherty KR; Adamali HI; Gibbons MA; Troy L; Forrest IA; Lasky JA; Spencer LG; Golden J; Scholand MB; Chaudhuri N; Perrella MA; Lynch DA; Chambers DC; Kolb M; Spino C; Raghu G; Goldberg HJ; Rosas IO;
    Lancet Respir Med; 2023 Jan; 11(1):87-96. PubMed ID: 36075242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Design and Rationale of the Trail1 Trial: A Randomized Double-Blind Phase 2 Clinical Trial of Pirfenidone in Rheumatoid Arthritis-Associated Interstitial Lung Disease.
    Solomon JJ; Danoff SK; Goldberg HJ; Woodhead F; Kolb M; Chambers DC; DiFranco D; Spino C; Haynes-Harp S; Hurwitz S; Peters EB; Dellaripa PF; Rosas IO;
    Adv Ther; 2019 Nov; 36(11):3279-3287. PubMed ID: 31515704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of antifibrotics in the treatment of rheumatoid arthritis-associated interstitial lung disease.
    Liang M; Matteson EL; Abril A; Distler JHW
    Ther Adv Musculoskelet Dis; 2022; 14():1759720X221074457. PubMed ID: 35186127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antifibrotic Agents in Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Systematic Review and Meta-Analysis.
    Jang JH; Ko J; Jung SY; Kim DW; Oh JH; Kim TJ; Park JH; Choi M; Lee JH
    Life (Basel); 2023 Dec; 13(12):. PubMed ID: 38137919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Study Analysing Progression and Survival of Patients with Idiopathic Pulmonary Fibrosis with Preserved Lung Function on Antifibrotic Treatment.
    Noor S; Nawaz S; Chaudhuri N
    Adv Ther; 2021 Jan; 38(1):268-277. PubMed ID: 33098554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overview of Rheumatoid Arthritis-Associated Interstitial Lung Disease and Its Treatment.
    Pugashetti JV; Lee JS
    Semin Respir Crit Care Med; 2024 Jun; 45(3):329-341. PubMed ID: 38484788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of nintedanib and pirfenidone on lung function and survival in patients with idiopathic pulmonary fibrosis in real-life setting.
    Santos G; Fabiano A; Mota PC; Rodrigues I; Carvalho D; Melo N; Novais-Bastos H; Alexandre AT; Moura CS; Guimarães S; Pereira JM; Carvalho A; Morais A
    Pulm Pharmacol Ther; 2023 Dec; 83():102261. PubMed ID: 37758002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival and quality of life in rheumatoid arthritis-associated interstitial lung disease after lung transplantation.
    Yazdani A; Singer LG; Strand V; Gelber AC; Williams L; Mittoo S
    J Heart Lung Transplant; 2014 May; 33(5):514-20. PubMed ID: 24630861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment Outcomes for Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Real-World, Multisite Study of the Impact of Immunosuppression on Pulmonary Function Trajectory.
    Matson SM; Baqir M; Moua T; Marll M; Kent J; Iannazzo NS; Boente RD; Donatelli JM; Dai J; Diaz FJ; Demoruelle MK; Hamblin MB; Mathai SK; Ryu JH; Pope K; Walker CM; Lee JS
    Chest; 2023 Apr; 163(4):861-869. PubMed ID: 36470416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases.
    Torrisi SE; Kahn N; Wälscher J; Sarmand N; Polke M; Lars K; Eichinger M; Heussel CP; Palmucci S; Sambataro FM; Sambataro G; Sambataro D; Vancheri C; Kreuter M
    BMC Pulm Med; 2019 Nov; 19(1):213. PubMed ID: 31718637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival differences in rheumatoid arthritis interstitial lung disease and idiopathic pulmonary fibrosis may be explained by delays in presentation: results from multivariate analysis in a monocentric UK study.
    Dubey S; Woodhead F
    Rheumatol Int; 2024 Jan; 44(1):99-105. PubMed ID: 38085367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence, incidence and cause-specific mortality of rheumatoid arthritis-associated interstitial lung disease among older rheumatoid arthritis patients.
    Sparks JA; Jin Y; Cho SK; Vine S; Desai R; Doyle TJ; Kim SC
    Rheumatology (Oxford); 2021 Aug; 60(8):3689-3698. PubMed ID: 33462611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-World Clinical Profile and Safety of Nintedanib in Systemic Sclerosis-Associated Interstitial Lung Disease: A Subgroup Analysis of Interstitial Lung Disease Data From an Interstitial Lung Disease (ILD) Specialty Clinic in India.
    Behera AK; Sharma P; Tg R; Kumar V; Pati SK; Sinha K
    Cureus; 2024 Jul; 16(7):e65579. PubMed ID: 39192903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Correlation between dyslipidemia and rheumatoid arthritis associated interstitial lung disease].
    Wu Q; Cai YM; He J; Huang WD; Wang QW
    Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Dec; 55(6):982-992. PubMed ID: 38101778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of interstitial lung disease among black rheumatoid arthritis patients.
    McFarlane IM; Zhaz SY; Bhamra MS; Burza A; Kolla S; Alvarez MR; Koci K; Taklalsingh N; Pathiparampil J; Freeman L; Kaplan I; Kabani N; Ozeri DJ; Watler E; Frefer M; Vaitkus V; Matthew K; Arroyo-Mercado F; Lyo H; Zrodlowski T; Feoktistov A; Sanchez R; Sorrento C; Soliman F; Valdez FR; Dronamraju V; Trevisonno M; Grant C; Clerger G; Amin K; Dawkins M; Green J; Moon J; Fahmy S; Waite SA
    Clin Rheumatol; 2019 Dec; 38(12):3413-3424. PubMed ID: 31471819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.